Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Generic Ticagrelor 90 mg vs Brilinta 90 mg in Healthy Thai Volunteers (Fasting)
TCTR20220822001Phase 1Not yet recruiting
- Sponsor
- International Bio Service
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ticagrelor (2 arms), sponsored by International Bio Service. Primary endpoint: Primary pharmacokinetic bioequivalence endpoints. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
ticagrelor
Beyond the preview
Go deeper on TCTR20220822001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20220822001.